Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 108

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 108
---
 | ​                 | ​ | ​ | ​                     | ​ | ​ |                           | ​ | ​ | ​                                           | ​ | ​ | ​                     | ​ | ​ | ​          | ​ | ​ | ​          | ​ |
| ​ | 2025PROXY STATEMENT SUMMARY | ​ | ​ | CORPORATEGOVERNANCEAND BOARDMATTERS | ​ | ​ | AUDITMATTERS | ​ | ​ | EXECUTIVEOFFICERS | ​ | ​ | EXECUTIVECOMPENSATION | ​ | ​ | STOCKOWNERSHIPINFORMATION | ​ | ​ | INFORMATIONABOUT THEANNUALMEETING ANDVOTING | ​ | ​ | ADDITIONALINFORMATION | ​ | ​ | APPENDIX A | ​ | ​ | APPENDIX B | ​ |

TABLE OF CONTENTS STOCK OWNERSHIP INFORMATION

| ​ | ​ | Stock Ownership Information | ​ |

Principal Stockholders The following table sets forth information, to the extent known by us or ascertainable from public filings, regarding the beneficial ownership of our common stock as of April 17, 2025 (except where otherwise noted), by: • each of our directors; • each of our named executive officers; • each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; and • all of our directors and executive officers as a group. Beneficial ownership is determined in accordance with SEC rules. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include shares of common stock issuable upon the vesting of RSUs, or the exercise of stock options that are immediately exercisable or exercisable, in each case, within 60 days of April 17, 2025. Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. Percentage ownership calculations for beneficial ownership are based on 46,290,830 outstanding shares of our common stock at the close of business on April 17, 2025. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of: Pacira BioSciences, Inc.
2000 Sierra Point Parkway
Suite 900
Brisbane, California 940